Blood Res.  2014 Mar;49(1):69-72. 10.5045/br.2014.49.1.69.

Pure erythroid leukemia in advanced breast cancer

• Niscola P
• Tendas A
• Minelli M
• Perrotti A
• de Fabritiis P
• Del Poeta

• KMID: 2172828
• DOI: http://doi.org/10.5045/br.2014.49.1.69

Abstract

No abstract available.

MeSH Terms

Breast Neoplasms*
Breast*
Leukemia*

Figure

• 

  Fig. 1 Bone marrow smears (×400, panoptical staining) showing several erythroblasts in different maturation phases with clear dyserythropoietic features (maturative asynchronism, cytoplasmic blebs). (A) A bone marrow smear revealed megaloblastoid proerythroblasts with polychromatophilic cytoplasm, multiple cytoplasmic blebs, and polylobated hyperdiploid nucleus with finely dense chromatin. (B) A bone marrow smear revealed giant proerythroblast with scarce basophilic cytoplasm and round nucleus with immature chromatin.

• 

  Fig. 2 Bone marrow trephine biopsy at diagnosis of pure erythroid leukemia. (A) Medium magnification (×200) shows a predominant bone marrow population composed of atypical immature erythroid precursors (more than 90% with nucleated cells). (B) High magnification (×400) revealed numerous atypical erythroid precursors and dyserythropoiesis. (C) Glycophorin-A immunostain expressed by the atypical erythroid neoplastic precursors. (D) Linker for activated T-cells immunostain shows dysmegakaryocytopoiesis with a micromegakaryocytes and a population of immature megakaryoblasts.

Reference

1. Wang SA, Hasserjian RP. Erythroid proliferations in myeloid neoplasms. Hum Pathol. 2012; 43:153–164. PMID: 22154053.

2. Liu W, Hasserjian RP, Hu Y, et al. Pure erythroid leukemia: a reassessment of the entity using the 2008 World Health Organization classification. Mod Pathol. 2011; 24:375–383. PMID: 21102413.

3. Liu CJ, Hong YC, Yang CF, et al. Clinicopathologic features and outcome of acute erythroid leukemia based on 2008 revised World Health Organization classification. Leuk Lymphoma. 2012; 53:289–294. PMID: 21780998.

4. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114:937–951. PMID: 19357394.

5. Guo C, Inghirami G, Ibrahim S, Sen F. Epistaxis and severe weakness in a patient with multiple myeloma. Therapy-related acute myeloid leukemia, pure erythroid leukemia. Arch Pathol Lab Med. 2006; 130:1075–1076. PMID: 16831041.

6. Funakoshi Y, Matsuoka H, Yamamoto K, et al. Therapy-related pure erythroid leukemia with hepatic infiltration and hemophagocytic syndrome. Intern Med. 2011; 50:3031–3035. PMID: 22185999.

7. Xu M, Finn LS, Tsuchiya KD, Thomson B, Pollard J, Rutledge J. Pure erythroid leukemia following precursor B-cell lymphoblastic leukemia. Pediatr Dev Pathol. 2012; 15:76–78. PMID: 21877942.

8. Sadrzadeh H, Hasserjian R, Fathi AT. Pure erythroid leukemia evolving from a therapy-related myelodysplastic syndrome secondary to treatment for chronic lymphocytic leukemia. Am J Hematol. 2013; 88:240–241. PMID: 22565525.

9. Pagano L, Pulsoni A, Mele L, et al. Acute myeloid leukemia in patients previously diagnosed with breast cancer: experience of the GIMEMA group. Ann Oncol. 2001; 12:203–207. PMID: 11300325.

10. Ayala RM, Martinez-Lopez J, Albizua E, Diez A, Gilsanz F. Clinical significance of Gata-1, Gata-2, EKLF, and c-MPL expression in acute myeloid leukemia. Am J Hematol. 2009; 84:79–86. PMID: 19097174.